Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence

Lenalidomide is approved for the treatment of transfusion‐dependent (TD) del(5q) myelodysplastic syndromes (MDS). However, few data are available in patients with transfusion‐independent (TI) del(5q) MDS. In the first, observational, part of this 2‐part study, we assessed the impact of transfusion d...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Med
Main Authors: Oliva, Esther N., Lauseker, Michael, Aloe Spiriti, Maria Antonietta, Poloni, Antonella, Cortelezzi, Agostino, Palumbo, Giuseppe A., Balleari, Enrico, Sanpaolo, Grazia, Volpe, Antonio, Ricco, Alessandra, Ronco, Francesca, Alati, Caterina, D'Errigo, Maria Grazia, Santacaterina, Irene, Kündgen, Andrea, Germing, Ulrich, Latagliata, Roberto
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2015
Teme:
Clinical Cancer Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123712/
https://ncbi.nlm.nih.gov/pubmed/26376955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.523
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki